Abstract: The disclosure relates to a method for treating a viral pulmonary infection (e.g., COVID-19 infection), the method comprising the step of delivering a composition comprising at least one bronchodilator or a pharmaceutically acceptable salt thereof and at least one pulmonary surfactant or a pharmaceutically acceptable salt thereof to the airway of a subject in need of treatment for the pulmonary viral infection.

Abstract: The disclosure relates to a method for treating a viral pulmonary infection (e.g., COVID-19 infection), the method comprising the step of delivering a composition comprising at least one bronchodilator or a pharmaceutically acceptable salt thereof and at least one pulmonary surfactant or a pharmaceutically acceptable salt thereof to the airway of a subject in need of treatment for the pulmonary viral infection.

Abstract: The disclosure relates to a method for treating a viral pulmonary infection (e.g., COVID-19 infection), the method comprising the step of delivering a composition comprising various combinations of (i) at least one of an interferon or an interferon inducer; (ii) at least one bronchodilator or a pharmaceutically acceptable salt thereof; (iii) at least one pulmonary surfactant or a pharmaceutically acceptable salt thereof; and (iv) at least one of particles comprising at least one of metal having antiviral properties and particles comprising metal compounds having antiviral properties; to the airway of a subject in need of treatment for the pulmonary viral infection.

Abstract: The disclosure relates to a method for treating a viral pulmonary infection (e.g., COVID-19 infection), the method comprising the step of delivering a composition comprising at least one bronchodilator or a pharmaceutically acceptable salt thereof and at least one pulmonary surfactant or a pharmaceutically acceptable salt thereof to the airway of a subject in need of treatment for the pulmonary viral infection.